An Efficacy, Safety Study to Evaluate Multiple Subcutaneous SHR-1918 in Combination With Lipid-Lowering Drugs for the Stable Treatment of Hyperlipidemic Patients With Poor Lipid Control-A Multicenter, Randomized, Double-Blind, Placebo-Parallel-Controlled, Phase II Clinical Study
Latest Information Update: 16 Mar 2026
At a glance
- Drugs SHR-1918 (Primary)
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Sponsors Beijing Suncadia Pharmaceuticals
Most Recent Events
- 16 Mar 2026 removed 3875803 since the abstract has data of phase I trial source has been integrated in 353752
- 02 Feb 2026 Status changed from active, no longer recruiting to completed.
- 14 May 2024 Status changed from recruiting to active, no longer recruiting.